EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudie

Tinzaparin Pharmacokinetics in Patients with Cancer: A Comparative Modeling Study

Xavier Delavenne iD, Jean Escal iD, Dominique Helley, Laurent Bertoletti iD, Nicolas Falvo, Isabelle Mahé iD, Benjamin Crichi, Francis Couturaud, Marie-Antoinette Sevestre, Michel Pavic, Laetitia Mauge, Sara Zia-Chahabi und 5 weitere

Thrombosis and Haemostasis · 2026-11 · 126 (11) · 1157-1165

DOI: 10.1055/a-2740-1841 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 25.11.2025. Verfasst von Xavier Delavenne und 16 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Pharmacologie et Toxicologie, CHU de Saint-Etienne, Saint-Priest-en-Jarez, France. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Models, Biological, Neoplasms, Thrombosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Assistance Publique - Hôpitaux de Paris, French Ministry of Health, Assistance Publique – Hôpitaux de Paris.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer-associated thrombosis (CAT) is common and a leading cause of mortality in patients with cancer. In specific CAT scenarios, low-molecular-weight heparins (LMWHs), including tinzaparin, are preferred over direct oral anticoagulants. Despite the importance of understanding LMWH pharmacokinetics (PK) in cancer for optimizing CAT management, available data remain limited. To compare tinzaparin PK in cancer and non-cancer patients by developing a population PK model. This prospective, multicenter, case–control trial enrolled patients receiving once-daily subcutaneous tinzaparin at a therapeutic dose of 175 IU·kg−1, including matched cancer and non-cancer patients. Plasma anti-Xa activity was measured at multiple time points and analyzed using a non-linear mixed-effect modeling. A PK model was developed, and covariate effects were assessed for parameters of the model. The impact of cancer on tinzaparin PK was evaluated by incorporating cancer status as a categorical covariate. A total of 333 patients (including 46 matched cancer and non-cancer patients) were included in the analysis. A monocompartmental model with first-order absorption best described tinzaparin PK. The volume of distribution was associated with body weight, while clearance and anti-Xa activity were associated with creatinine clearance. No significant differences were observed between matched cancer and non-cancer patients in anti-Xa activity exposure at day 1 and steady state. PK profiles were comparable between cancer and non-cancer patients. Additionally, further studies should clarify the role of renal function in guiding tinzaparin dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibrinolytic AgentsModels, BiologicalNeoplasmsThrombosisTinzaparinAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedCase-Control StudiesFactor Xa InhibitorsHeparin, Low-Molecular-WeightProspective Studies

Substanzen

Factor Xa InhibitorsFibrinolytic AgentsHeparin, Low-Molecular-WeightTinzaparin

Autor:innen und Institutionen

  • Laboratoire de Pharmacologie et Toxicologie, CHU de Saint-Etienne, Saint-Priest-en-Jarez, France.
  • INSERM UMR1059 SAINBIOSE, Equipe Dysfonction Vasculaire et de l'Hémostase, Université Jean-Monnet, Saint-Priest-en-Jarez, France.
  • Service d'hématologie biologique, Assistance Publique Hôpitaux de Paris-Centre Université de Paris (APHP-CUP), Hôpital Européen Georges-Pompidou, Paris, France.
  • INSERM UMR-S970 Paris Cardiovascular Research Centre, Team Endotheliopathy and Hemostasis Disorders, Paris Cité University, Paris, France.
  • Université Paris Cité, Paris, France.
  • Service de médecine vasculaire et thérapeutique, CHU Saint-Etienne, Saint-Priest-en-Jarez, France.

ORCID-Profile: Xavier Delavenne, Jean Escal, Laurent Bertoletti, Isabelle Mahé

Förderung

  • Assistance Publique - Hôpitaux de Paris
  • French Ministry of Health
  • Assistance Publique – Hôpitaux de Paris

Zitieren

APA

Delavenne, X., Escal, J., Helley, D., Bertoletti, L., Falvo, N., Mahé, I., Crichi, B., Couturaud, F., Sevestre, M. A., Pavic, M., Mauge, L., Zia-Chahabi, S., Vilfaillot, A., Djadi-Prat, J., Mismetti, P., Meyer, G., & Sanchez, O. (2026). Tinzaparin Pharmacokinetics in Patients with Cancer: A Comparative Modeling Study. Thrombosis and Haemostasis, 126(11), 1157-1165. https://doi.org/10.1055/a-2740-1841

Vancouver

Delavenne X, Escal J, Helley D, Bertoletti L, Falvo N, Mahé I, et al. Tinzaparin Pharmacokinetics in Patients with Cancer: A Comparative Modeling Study. Thrombosis and Haemostasis. 2026;126(11):1157-1165. doi:10.1055/a-2740-1841

BibTeX
@article{Delavenne2026,
  author = {Delavenne, Xavier and Escal, Jean and Helley, Dominique and Bertoletti, Laurent and Falvo, Nicolas and Mahé, Isabelle and Crichi, Benjamin and Couturaud, Francis and Sevestre, Marie-Antoinette and Pavic, Michel and Mauge, Laetitia and Zia-Chahabi, Sara and Vilfaillot, Aurélie and Djadi-Prat, Juliette and Mismetti, Patrick and Meyer, Guy and Sanchez, Olivier},
  title = {Tinzaparin Pharmacokinetics in Patients with Cancer: A Comparative Modeling Study},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  volume = {126},
  number = {11},
  pages = {1157--1165},
  doi = {10.1055/a-2740-1841}
}
Kostenlos starten →